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Summary Statement 
To the best of our knowledge, this is the first case report of Ritonavir-associated toxicity 
mimicking retinitis pigmentosa in a HIV infected patient on Highly-Active Antiretroviral 
Therapy. 
Abstract 
Purpose: To report Ritonavir-associated retinal pigment epithelium toxicity in a patient 
infected with the human immunodeficiency virus (HIV) on Highly-Active Antiretroviral 
Therapy (HAART) including ritonavir. 
 
Methods: Retrospective single case report. We describe a case of gradual-onset of blurry 
vision in both eyes in a HIV-positive male. Visual acuity, clinical examination findings, and 
functional testing (electroretinogram and Goldmann perimetry) were reviewed. Diagnostic 
imaging including fundus photography, spectral domain optical coherence tomography (SD-
OCT), fluorescein angiography (FA) and fundus autofluorescence (FAF) were assessed.  
 
Results: 59-year-old HIV-infected male, treated with ritonavir for eight years, presented with 
a history of decreased night vision and peripheral field loss. Ophthalmologic examination 
confirmed the diagnosis of retinal toxicity. Goldmann perimetry showed areas of central and 
para-central scotomas. ERGs demonstrated mild to moderate photoreceptor dysfunction. 
Fundus examination revealed a diffuse pattern of RPE mottling in both eyes. SD-OCT 
confirmed the presence of choroidal thinning while FAF showed mottled 
hypoautofluorescence.  
 
Conclusions:  Although ritonavir-associated retinal toxicity is clinically uncommon, the 
clinical features of our findings support this diagnosis. Consideration of HAART-associated 
retinal toxicity should be given to the differential diagnosis in HIV-positive patients with 
retinopathy of unclear etiology. This report also highlights the need for constant monitoring 








Many medications have been associated with retinal toxicity. The retinal pigment epithelium 
is a likely target for systemically administered compounds, since the underlying choroid is 
highly vascularized. The blood-retinal barrier prevents many systemically administered drugs 
from entering the eye via the circulatory system. Yet many medications that are administered 
systemically may still gain access to the eye and evoke degeneration of the RPE, 1,2  and have 
been associated with toxic retinopathy, 3,4 optic neuritis, 5,6  anterior uveitis and cystoid 
macular edema. 7   
We report a case of an HIV positive patient, who presented ritonavir-associated toxicity 




A 59-year-old HIV-infected male, presented with a history of slowly progressive decreased 
night vision in both eyes and peripheral visual field loss of two years duration. He had been 
placed on antiretroviral therapy with protease inhibitors ritonavir (Norvir, Abbott 
Laboratories) 100mg/day and atazanavir (Reyataz) 300mg/day, and a nucleoside reverse 
transcriptase inhibitor tenofovir/emtricitabine (Truvada, Gilead Sciences International 
Limited) 245/200mg/day starting 8 years prior, and other medications such as: reosuvastatin 
10mg/day, amlodopine 5mg/day and aspirin 75mg/day. CD4+ T cell count was 330 cells per 
microliter, viral load was undetectable, and there was no previous history of AIDS-defining 
illness. There was no record of previous didanosine use, nor of anti-tuberculous drugs. The 
patient refers no family history of retinal disorders and has no history of HIV retinopathy or 
CMV retinitis. 
Best-corrected visual acuity measured 6/15 in the right eye and 6/9.5 in the left eye. Anterior 
segment examination and intraocular pressures were normal in both eyes. Dilated 
fundoscopic examination revealed scattered bone specule-like pigment changes on the mid-
peripheral retina of both eyes (Figure 1 a. and b) while wide-field FAF revealed more 
extensive retinal involvement than stereo fundus biomicroscopy alone, highlighting mottled 
hypofluorescence, and sparing the macula area in the left eye (Figure 1 c. and d.).  
A fluorescein angiogram was performed, which showed bilateral bright punctate window 
defects resulting in a speckled appearance throughout the fundus and pigmentary clumping 
mostly in the mid-periphery. (Figure 2 a. and b.) 
 SD-OCT demonstrated thinning of the retina, especially in the outer nuclear layer, which 
corresponds to loss of photoreceptors (Figure 2 c. and d.) Visual field test (Goldmann 
perimetry) showed areas of paracentral scotomas. The patient subsequently underwent 
electroretinogram (ERG) testing. Pattern ERG P50 was undetectable bilaterally. Rod ERGs 
were severely subnormal bilaterally. Bright flash ERG a-waves were markedly subnormal 
and waveforms electoronegative bilaterally. Photopic 30Hz flicker ERGs were markedly 
delayed and of subnormal amplitude bilaterally. Single flash cone ERGs have an abnormal 
broad a-wave and sharply rising b-wave without oscillatory potentials and both a- and b- 
wave amplitudes were subnormal bilaterally. These ERG features were consistent with a rod-
cone dystrophy with an additional inner retinal involvement suggestive of retinal toxicity.  
The diagnosis of toxic retinopathy associated with ritonavir was made based on clinical 




Many etiologies can cause retinopathy phenocopying RP (pseudoretinitis pigmentosa). 
Correctly differentiating these conditions from RP is imperative because these conditions are 
generally treatable, unlike RP. The causes of pseudoretinitis pigmentosa, based on etiology, 
include infection such as congenital rubella, toxoplasmosis, syphillis, Lyme disease; 
inflammation (retinal vasculitis, old posterior uveitis); autoimmunity (autoimmune 
retinopathy, cancer-associated retinopathy, acute zonal occult outer retinopathy); trauma 
(intraocular foreign bodies such as siderosis, or blunt trauma, such as severe commotio 
retinae); and drug toxicity to chloroquine/hydrohychloroquine, phenothiazides, or 
thioridazine. 8 In the present case, the combination of a good clinical history and a complete 
ophthalmic examination contributed significantly to diagnosis. 
Three drugs used in the treatment of AIDS-related disorders have previously been linked with 
retinal epitheliopathy: the protease inhibitor ritonavir; clofazimine, used in the management 
of atypical mycobacterial infections, and the reverse transcriptase inhibitor didanosine. 5 The 
only agent common to our patient and previous cases is ritonavir, a HIV protease inhibitor, 
which exhibits anti-neoplastic effects independent from its ability to inhibit HIV protease. 9   
 
Ocular complications resulting from ritonavir are rare and can include blepharitis, 
conjunctivitis, iritis, and uveitis. 10 Roe et al. 11 reported the occurrence of a retinal pigment 
epitheliopathy associated with macular telangiectasis and intraretinal crystal deposits in HIV-
positive patients receiving long-term ritonavir as part of highly active antiretroviral therapy. 
Both hypertrophic and atrophic changes were seen; and these did not involve the fovea. 
Intraretinal crystalline deposits and other features reminiscent of idiopathic parafoveal 
telangiectasis were also seen, in all 3 patients. However, none of these cases involving 
ritonavir toxicity described fundus appearance mimicking a pseudo-retinitis pigmentosa 
fundus. Retinitis pigmentosa-like fundus has been reported by Muccioli et al. 12 in a HIV 
positive patient and it was attributed to didanosine use; however, this patient was on ritonavir 
therapy too. 
 It is not yet known the mechanism by which ritonavir injures the RPE, the neurosensory 
retina and the choriocapillaris, but it appears to be related to the drug's effect on 
mitochondrial DNA. Based on rodent studies, the proposed mechanism of ritonavir retinal 
toxicity has been phospholipidosis. 13 
 
Besides the retina, liver, thyroid and kidney have also been described as targets for dose-
related ritonavir toxicity. 13 Liver dysfunction was one characteristic common to the 3 
patients in Roe's report; 11 whereas our patient had normal liver serum enzymes, thyroid 
hormone blood tests and blood and urine kidney function tests. 
 
FAF is a useful tool as it displayed a more extensive disruption of the RPE than stereo fundus 
biomicroscopy alone. The involvement of the macula of the right eye explains the poorer 
vision in that eye compared to the left eye, where the macula appears to have normal FAF. 
 
This report shows the need for ophthalmological screening and constant monitoring of 
patients using the ritonavir for early detection of possible retinal toxicity. Identification of 
this is important, especially if a reasonable alternative is available. Our case report may 
represent further evidence toward the retinal toxicity of the protease inhibitor ritonavir. To 
the best of our knowledge, this is the first case report of ritonavir toxicity with fundus 
appearance mimicking a pseudo-retinitis pigmentosa fundus. 
 
 
 
 
 
 
 
 
 
 
 
